Natco’s AP formulations unit gets USFDA Form 483 with 4 observations | Hyderabad News

Hyderabad: Natco Pharma Limited’s finished dosage formulations manufacturing facility at Parawada in Visakhapatnam, Andhra Pradesh, has received Form 483 with four observations from the United States Food and Drug Administration (USFDA).The Form 483 was issued after an inspection of the facility conducted from August 17 to August 21, 2026, by the US drug watchdog. A Form 483 is an official report filed by US FDA inspectors to a company’s management in case its investigators observe violations of US federal laws or regulations during an on-site inspection.Natco said in a regulatory filing that it believes the observations to be procedural in nature and expressed confidence that it will address them comprehensively within the stipulated timelines.The Hyderabad-based company develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.The company is focused on oncology targeted therapies in the domestic market and limited-competition molecules in the US market.Natco’s manufacturing facilities are approved by several regulatory authorities, including the US FDA, Brazil’s ANVISA, Health Canada and World Health Organization, and cater to more than 50 global markets.